Prescription drug · NDA
Cosela (trilaciclib) NDC 73594-0101
Trilaciclib dihydrochloride 300 mg/20mL · Injection, Powder, Lyophilized, For solution · Intravenous · Pharmacosmos Therapeutics Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 73594-0101-1 | 73594010101 | 1 VIAL, GLASS in 1 CARTON (73594-0101-1) / 20 mL in 1 VIAL, GLASSMarketed from Aug 25, 2025 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Cosela
- Generic name (nonproprietary)
- trilaciclib
- Active ingredients
- Trilaciclib dihydrochloride — 300 mg/20mL
- Dosage form
- Injection, Powder, Lyophilized, For solution
- Route
- Intravenous
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 214200
- Marketing start
- Listing expires
- Other FDA classes
- Cyclin-dependent Kinase 4 Inhibitors (Mechanism)Cyclin-dependent Kinase 6 Inhibitors (Mechanism)Multidrug and Toxin Extrusion Transporter 1 Inhibitors (Mechanism)Multidrug and Toxin Extrusion Transporter 2 K Inhibitors (Mechanism)Organic Cation Transporter 2 Inhibitors (Mechanism)
- Identifiers
- Product ID 73594-0101_8b1ee2ee-7097-4ded-9755-ffac490337c1SPL ID 8b1ee2ee-7097-4ded-9755-ffac490337c1SPL set ID b3179c19-78f3-4bf1-b73e-7f7638522ab1RxCUI 2479705, 2479710UNII 4BX07W725TUPC 0373594010114
- Pharmacologic class
- Kinase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N473594010101followed by a unit qualifier and the quantityPackage 73594-0101-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). COSELA is a kinase inhibitor indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 214200
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Coselatrilaciclib | Trilaciclib dihydrochloride 300 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | G1 Therapeutics, Inc. | 73462-101 |